highlighted here. That collaboration requires some Professor Tim Eden has held senior academic and clinical
refocusing by professional medical and nursing organisations, positions in Bristol, Edinburgh, London and Manchester where
parent groups, NGOs, WHO and governments around the he was the Teenage Cancer Trust Professor of Teenage Oncology.
world. Cancer and other noncommunicable diseases are He was formerly President of SIOP (International Society of
becoming an increasing threat to life which cannot be ignored Paediatric Oncologists). He retired in 2008 but remains active
any longer. l in a number of organizations working in the field of childhood
and teenage cancer in the UK and in developing countries.
McGregor, LM, Metzger ML, Sanders R, Santana VM. Pediatric Cancers in the New 2006; 47: 489 (abstract PK020)
Millennium: dramatic progress, new challenges. Oncology 2007; 21(7): 809 – 820 14.
Hunger SP, Sung L, Howard SC. Treatment strategies and regimens of Graduated
Ferlay J, Bray F, Pisani P, Parkin MD. Globocan 2002: Cancer Incidence, Mortality and Intensity for Childhood Acute Lymphoblastic leukaemia in Low-Income Countries: A
Prevalence Worldwide. IARC CancerBase no 5 version 2.0 2004 Lyon: IARC Press Proposal. Pediatric Blood and Cancer 2009; 52: 559 – 565.
(International Agency for Cancer Research) 15.
Barr RD, Sala A, Mato G et al. A formulary for pediatric oncology in developing
Eden T. Translation of cure for acute lymphoblastic leukaemia to all children. British countries. Pediatric Blood and Cancer 2005; 44: 433 – 435.
Journal of Haematology 2002; 118(4): 945 – 951. 16.
You D, Wardlaw T, Salama P, Jones G. Levels and trends in under 5 mortality, 1990 –
Pui C-H, Schrappe M, Masera G et al. Ponte di Legno Working Group: Statement on 2008. The Lancet 2012; Vol 315: 100 – 102.
the Right of Children with leukaemia to have full access to essential treatment and 17.
UNICEF, WHO, The World Bank, UN Population Division, Child Mortality database
report on the 6th International Childhood ALL Workshop. Leukaemia 2004; 18: 1043 (CME info). www.childmortality.org (accessed August 20th 2009)
Sachs JD. Health in the developing world: achieving the Millennium Goals. Bulletin of
Masera G, Baez F, Biondi A et al. North-South twinning in paediatric haematology- the World Health Organization 2004; 82(12): 947 – 949.
oncology: the La Mascota programme, Nicaragua. Lancet 1998; 352: 1923 – 1926.
Cure 4 Kids-http:// www.cure 4 kids.org.
Harif M, Barsaoui S, Benchokroun S et al. Treatment of Childhood Cancer in Africa:
Sachdeva A, Jain V, Yadav SP et al. Move to alternative medicine – why? when? The
preliminary results of the French-African Paediatric Oncology Group. Arch. Paediatr
Indian scenario. Pediatric Blood and Cancer 2005; 45: 578 (abstract PR004).
2005; 12: 851 – 853.
7. Israels T, Chirambo C, Caron H et al. The guardian’s perspective on pediatric
Ribeiro RC, Pui C-H et al. Saving the Children – improving childhood cancer
treatment in Malawi and factors affecting adherence. Pediatric Blood and cancer
treatment in developing countries. New England Journal of Medicine 2005; 352: 2158
2008; 51(5): 639 – 642.
8. Howard SC, Carnpana D, Couston-Smith E et al. Development of a regional flow
Burton A. The UICC “My Child Matters” initiative awards: combating cancer in
cytometry center for diagnosis of childhood leukaemia in Central America. Leukaemia
children in the developing world. Lancet Oncology 2006; 7: 13 – 14.
2005; 19(3): 323 – 325.
Ribeiro RC, Steliorova-Foucher E, Magrath I et al. Baseline status of paediatric
Harris E, Tanner M. Health Technology Transfer. BMJ 2000; 321: 817 – 820.
oncology care in ten low-income or mid-income countries receiving “My Child
Matters” support: a descriptive study. Lancet Oncology 2008; 9: 721 – 729. Sikora K, Advani S, Korottchouk V et al. Essential drugs for cancer therapy: a World
10. Health Organisation consultation. Annals of Oncology 1999; 10(4): 385 – 390
Arora RS, Eden T, Pizer B. The problem of treatment abandonment in children from
developing countries with cancer. Pediatric Blood and Cancer 2007; 49: 941 – 946. 2005 World Bank Indicators, Washington: International bank for Reconstruction and
11. development/The World Bank: 2009
Howard SC, Pedrosa M, Lins M et al. Establishment of a pediatric oncology program
and outcomes of childhood lymphoblastic leukaemia in a resource-poor area. JAMA Jack A, Glaxo-Smith-Kline tops the list of companies making drugs accessible to poor
2004; 291: 2471 – 2475. countries. British Medical Journal 2008; 336: 1396.
Metzger ML, Howard SC, Fu LC et al. Outcome of childhood acute lymphoblastic Wilimas JA, Donahue N, Chammas G et al. Training subspecialty nurses in developing
leukaemia in resource-poor countries. Lancet 2003; 362: 706 – 708. countries: methods, outcome and cost. Medical and Pediatric Oncology 2003; 41(2):
13. 136 – 140.
Mostert S, Sitaresmi H, Gundy C. Influence of socio-economic status on childhood
acute lymphoblastic leukaemia treatment in Indonesia. Pediatric Blood and Cancer
CANCER CONTROL 2013 107